Maze Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 31.93 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.72B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also deve...